EYE103

Phase 2Small molecule

EEyeBiotech Ltd.

EYE103 is one of 4 small molecule programs targeting Diabetic Macular Edema (DME). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Macular Edema (DME)Active, not recruiting

Neovascular Age-Related Macular Degeneration (NVAMD)Recruiting

Diabetic Macular Edema (DME)Preclinical

Active, not recruiting

Neovascular Age-Related Macular Degeneration (NVAMD)Phase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Diabetic Macular Edema (DME)

#DrugCompanyPhaseTrials

Tabirafusp Tedromer

KKodiak Sciences Inc

Phase 3

1 2

Lucentis

Roche

Preclinical

2 3

EYE103

EEyeBiotech Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalActive, not recruiting

Diabetic Macular Edema (DME)

NCT06571045

Q1 2028

PreclinicalActive, not recruiting

Diabetic Macular Edema (DME)

NCT06957080

Q2 2028

Phase 2Recruiting

Neovascular Age-Related Macular Degeneration (NVAMD)

NCT07205887

Clinical

Trials by Indication[1]

Diabetic Macular Edema (DME)2 trials

A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema

Active, not recruiting·EEyeBiotech Ltd.·Preclinical·NCT06571045·984 enrolled

Active, not recruiting·EEyeBiotech Ltd.·Preclinical·NCT06957080·1,054 enrolled

Age-Related Macular Degeneration1 trial

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

Completed·EEyeBiotech Ltd.·Phase 1/2·NCT05919693·33 enrolled

Neovascular Age-related Macular Degeneration (NVAMD)1 trial

A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)

Recruiting·EEyeBiotech Ltd.·Phase 2·NCT07205887·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for EYE103. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EYE103 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EYE103. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EyeBiotech Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEyeBiotech Ltd.

EYE103

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Diabetic Macular Edema (DME)2 trials

Age-Related Macular Degeneration1 trial

Neovascular Age-related Macular Degeneration (NVAMD)1 trial

References

Drug Info

Quick Facts

Related News